Johannes F.E. Mann

机构：Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Katholische Stiftungshochschule München, KfH Kuratorium für Dialyse und Nierentransplantation, Kidney Centre · ORCID：0000-0002-3154-5332

发表论文 446 篇 · 总被引 49654 次 · h-index 86

代表论文

• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025 · New England Journal of Medicine · 被引 382)
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2024 · The Lancet Diabetes & Endocrinology · 被引 331)
• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (2025 · New England Journal of Medicine · 被引 284)
• Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (2025 · Circulation · 被引 64)
• Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials (2025 · Diabetes Care · 被引 57)
• COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics (2025 · Nephrology Dialysis Transplantation · 被引 29)